Glomerular Hyperfiltration and Cardiovascular Health

Glomerular hyperfiltration denotes a state in which the kidney’s filtration rate exceeds normal adaptive levels, often defined as an estimated glomerular filtration rate (eGFR) above the 95th percentile for age and sex. Initially regarded as benign or even protective, mounting evidence now implicates hyperfiltration in the early pathogenesis of cardiovascular disease. Mechanistically, sustained elevations in glomerular pressure and flow may induce endothelial dysfunction, promote arterial stiffness and trigger maladaptive remodelling of both renal and systemic vasculature. Clinically, hyperfiltration manifests in a spectrum of conditions—from obesity and metabolic syndrome to early diabetes and hypertension—and may presage microvascular injury in organs such as the heart and brain. The global significance lies in its potential to refine risk stratification: individuals with preserved or high eGFR may harbour hidden cardiovascular risk equivalent to that of established chronic kidney disease. Recognition of hyperfiltration as a modifiable risk marker invites targeted interventions, including metabolic control, blood‐pressure modulation and lifestyle measures, to mitigate long‐term cardiovascular burden.

Research from Nature Portfolio

Studies employing direct measures of insulin sensitivity have demonstrated that in overweight yet non‐diabetic individuals, glomerular hyperfiltration correlates more strongly with insulin resistance than with overall adiposity. This dissociation emphasises the role of metabolic dysregulation rather than body mass per se in driving renal haemodynamic changes and suggests that improving insulin action may attenuate hyperfiltration. In parallel, a genetic approach using Mendelian randomisation has sought to clarify whether intrinsic variations in eGFR causally influence coronary heart disease risk. Although observational links between low eGFR and coronary events remain robust, the genetic evidence has proven inconclusive, underscoring the need for further functional genomics to disentangle causation from confounding factors.

Glomerular Hyperfiltration and Cardiovascular Health publication trend

The graph below shows the total number of articles in glomerular hyperfiltration and cardiovascular health across all publications each year (not limited to Nature Index journals).

Technical terms

Glomerular hyperfiltration: A condition in which the filtration rate of the kidney exceeds the normal adaptive range, often identified when eGFR lies above a predefined high percentile for age and sex.

Estimated glomerular filtration rate (eGFR): A calculated index of kidney function derived from serum creatinine (or cystatin C), age, sex and race, used to approximate true glomerular filtration capacity.

Metabolic syndrome: A cluster of metabolic abnormalities—including central obesity, hypertension, dyslipidaemia and impaired glucose regulation—that together elevate cardiovascular and renal risk.

Insulin resistance: A state in which target tissues exhibit diminished response to circulating insulin, often requiring higher insulin levels to maintain normoglycaemia and associated with vascular dysfunction.

Mendelian randomisation: A genetic epidemiology method that uses inherited variants as proxies for modifiable exposures, aiming to assess causal relationships between those exposures and disease outcomes.

References

1. Renal hyperfiltration revisited—Role of the individual body surface area on mortality. European Journal of Internal Medicine (2023).
2. The Association Between Metabolic Syndrome, Hyperfiltration, and Long-Term GFR Decline in the General Population. Kidney International Reports (2023).
3. Association of Glomerular Hyperfiltration and Cardiovascular Risk in Middle-Aged Healthy Individuals. JAMA Network Open (2020).
4. Higher glomerular filtration rate is related to insulin resistance but not to obesity in a predominantly obese non-diabetic cohort. Scientific Reports (2017).
5. Mendelian Randomisation study of the influence of eGFR on coronary heart disease. Scientific Reports (2016).